11 recruiting. 11 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 11 | Recruiting 11 |
Follow Demyelinating Diseases: new trials by email Literature Review of Demyelinating Diseases trials Research Report on Demyelinating Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy OCR SC - Multiple Sclerosis | Phase 4 | Recruiting | Genentech, Inc. | 100 | 2026-09-02 | 2026-10-30 |
| Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis Silodosin 8 mg, Placebo - Multiple Sclerosis, Lower Urinary Track Symptoms | Phase 4 | Recruiting | Atlantic Health System | 60 | 2026-04-01 | 2026-05-29 |
| Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis Ublituximab, Ocrelizumab - Multiple Sclerosis | Phase 4 | Recruiting | Johns Hopkins University | 50 | 2026-02-10 | 2026-05-06 |
| Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study Eculizumab+IVMP, IVIG+IVMP, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 4 | Recruiting | Chinese PLA General Hospital | 200 | 2026-02-01 | 2026-03-12 |
| Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities Cryoneurolysis, Botulinum toxin - Centreal Neurological Condition, Acquired Brain Injury (Including Stroke) | Phase 4 | Recruiting | Oxford University Hospitals NHS Trust | 50 | 2025-12-02 | 2025-12-26 |
| Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis Ublituximab - Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting | Phase 4 | Recruiting | Northwestern University | 40 | 2025-11-28 | 2026-03-17 |
| Glucose Consumption in MS Using [F-18]FDG-PET [F-18]FDG - Multiple Sclerosis | Phase 4 | Recruiting | Brigham and Women's Hospital | 50 | 2025-05-31 | 2026-01-09 |
| ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS ETNATM-ProgMS - Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 4 | Recruiting | Novartis Pharmaceuticals | 224 | 2024-11-27 | 2026-05-15 |
| Home Based Infusions for Ocrelizumab Ocrelizumab at home - Multiple Sclerosis | Phase 4 | Recruiting | University of Colorado, Denver | 110 | 2021-03-01 | 2021-06-10 |
| Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis Fingolimod - Multiple Sclerosis | Phase 4 | Recruiting | Novartis Pharmaceuticals | 30 | 2020-10-12 | 2026-06-26 |
| Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) Immunoglobulin - CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 4 | Recruiting | University of Aarhus | 60 | 2020-06-04 | 2024-05-17 |
Multiple Sclerosis (8) · Multiple Sclerosis, Relapsing-Remitting (3) · Brain Injuries (1) · Charcot-Marie-Tooth disease, Type 1F (1) · Multiple Sclerosis, Chronic Progressive (1) · Muscle Spasticity (1) · Neuromyelitis Optica (1) · Pain (1) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (1) · Spinal Cord Injuries (1) · Stroke (1)
Autoimmune Diseases (11) · Autoimmune Diseases of the Nervous System (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Demyelinating Autoimmune Diseases, CNS (10) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Disease Attributes (2) · Pathologic Processes (2) · Brain Diseases (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Cerebrovascular Disorders (1) · Cranial Nerve Diseases (1)
ublituximab (2) · Botulinum Toxins (1) · Botulinum Toxins, Type A (1) · Fingolimod Hydrochloride (1) · Immunoglobulins (1) · Nerve Block (1) · incobotulinumtoxinA (1) · ocrelizumab (1) · silodosin (1)
Novartis Pharmaceuticals (2) · Atlantic Health System (1) · Brigham and Women's Hospital (1) · Chinese PLA General Hospital (1) · Genentech, Inc. (1) · Johns Hopkins University (1) · Northwestern University (1) · Oxford University Hospitals NHS Trust (1) · University of Aarhus (1) · University of Colorado, Denver (1)
United States (6) · Canada (1) · China (1) · Denmark (1) · Puerto Rico (1) · Taiwan (1) · United Kingdom (1)
Farrah J Mateen, MD, PhD (1) · Henning Andersen, MD,DMSc,PhD (1) · Shiv Saidha, MD (1) · Tarun Singhal, MD, MBBS (1) · Timothy L Vollmer, MD (1)
2018 (1)